Table 11.6a

Immunosuppression Use for Induction, 1996 to 2005

Recipients with Heart Transplants

  Year of Transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 2,343 2,293 2,348 2,188 2,199 2,202 2,155 2,057 2,016 2,126
With Immunosuppression Info 2,047 2,261 2,318 2,138 2,148 2,152 2,119 2,024 1,967 2,011
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 17.0% 18.0% 16.9% 12.0% 9.4% 7.7% 7.0% 7.9% 7.2% 6.8%
OKT3 14.6% 12.4% 9.9% 11.1% 8.7% 8.6% 5.4% 4.6% 3.7% 3.1%
Thymoglobulin 0.0% 0.0% 0.0% 2.5% 6.9% 10.7% 16.2% 12.9% 15.7% 14.9%
Zenapax 0.0% 0.0% 2.9% 7.2% 8.8% 13.4% 11.4% 14.6% 15.7% 15.3%
Simulect 0.0% 0.0% 0.2% 2.5% 5.1% 5.2% 7.0% 9.3% 10.2% 13.8%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.9% 0.7%
No Induction Drugs Recorded 68.7% 70.1% 70.5% 65.7% 62.8% 56.4% 55.1% 52.9% 52.8% 47.8%


Source: OPTN/SRTR Data as of May 1, 2006.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.